EAU24 Interview | Dr. Matthew Galsky reports the OS results of the CheckMate 274 study for the first time, showing benefit trends from adjuvant immunotherapy
Editor's note: The CheckMate 274 study is the first phase 3 clinical trial to obtain positive results in the field of adjuvant immunotherapy for urothelial cancer. It has been previously…